Parkinsonism is a rare neurological complication of cancer treatment. Although individual case reports of this syndrome have been reported, the clinical features and prevalence of this syndrome are unknown. We present 3 patients, encountered over 6 months at one institution, who developed parkinsonism after treatment with various chemotherapeutic agents. Parkinsonism was severe in 2 patients, affecting postural reflexes, speech, and swallowing. All 3 patients responded dramatically to treatment with levodopa, and parkinsonism spontaneously improved or remitted over months. This unusual complication of cancer therapy is treatable and may be underappreciated.

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.10344DOI Listing

Publication Analysis

Top Keywords

complication cancer
8
chemotherapy-induced parkinsonism
4
parkinsonism responsive
4
responsive levodopa
4
levodopa underrecognized
4
underrecognized entity
4
parkinsonism
4
entity parkinsonism
4
parkinsonism rare
4
rare neurological
4

Similar Publications

Ibrutinib treatment is often complicated by cardiovascular side effects (CVSEs). The objective of this retrospective pharmacogenetic study is to replicate a previously reported association of 'high-risk' patients, who are homozygous carriers of at least two of GATA4 rs804280 AA, KCNQ1 rs163182 GG, and KCNQ1 rs2237895 AA, with increased risk of hypertension or atrial fibrillation, and explore associations for other pharmacogenes (e.g.

View Article and Find Full Text PDF

This narrative review provides a comprehensive overview of the current status, recent advancements, and future directions in the management of metastatic spine disease using both radiotherapy and surgery. Emphasis has been put on the integrated use of radiotherapy and surgery, incorporating recent developments such as separation surgery, active dose sparing of the surgical field, and the implementation of carbon fiber-reinforced polymer implants. Future studies should explore the effects of minimizing the time between radiotherapy and surgery and investigate the potential of vertebral re-ossification after radiotherapy to obviate the need for stabilization surgery.

View Article and Find Full Text PDF

Background: Peritoneal metastasis (PM) after the rupture of hepatocellular carcinoma (HCC) is a critical issue that negatively affects patient prognosis. Machine learning models have shown great potential in predicting clinical outcomes; however, the optimal model for this specific problem remains unclear.

Methods: Clinical data were collected and analyzed from 522 patients with ruptured HCC who underwent surgery at 7 different medical centers.

View Article and Find Full Text PDF

Objective: To investigate the efficacy of laparoscopic sigmoid extraperitoneal colostomy combined with pelvic peritoneal closure in abdominoperineal resection for low rectal cancer.

Methods: We retrospectively analyzed the clinical data of 162 patients with low rectal cancer, who underwent laparoscopic abdominoperineal resection from January 2015 to January 2019 at the Affiliated Peace Hospital of Changzhi Medical College. Extraperitoneal stoma construction was performed in 98 patients (study group), while 64 patients (control group) underwent the procedure without suturing the pelvic peritoneum.

View Article and Find Full Text PDF

In recent times, innovative surgical robotics have emerged and gained widespread adoption. This study aimed to compare the perioperative outcomes associated with robot-assisted radical prostatectomy (RARP) using three different robotic surgical systems: da Vinci surgical system (DVSS), hinotori surgical robot system (HSRS), and Hugo robot-assisted surgery system (HRASS). Our study involved a retrospective analysis of clinical data from 149 individuals who received RARP from 2022 to 2024, utilizing the DVSS (n = 81), HSRS (n = 52), and HRASS (n = 16).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!